Alios BioPharma, Inc.

CLOSED

加利福尼亚州圣马特奥县, California, United Stateswww.aliosbiopharma.comPrivate51–100 employeesEstablished: 2006-01-01

Part of 强生

Clinical Trials

2 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2006

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

73.9%

Phase 2

21.7%

Not Applicable

4.3%

Trial Status Distribution

Active, not recruiting

4.3%

Completed

65.2%

Not yet recruiting

4.3%

Terminated

21.7%

Withdrawn

4.3%

Clinical Trials

Trials sponsored by this organization (23)

A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B

Phase 1

Completed

interventional

Mar 2018130 participants

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy Volunteers

Phase 1

Terminated

interventional

Mar 201827 participants

A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects

A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants

Phase 1

Completed

interventional

Sep 201742 participants

A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection

Phase 1

Terminated

interventional

Jul 201724 participants

Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers

Phase 1

Terminated

interventional

Jan 201754 participants

Hepatitis C Study with GT 1 2 and 3.

Phase 1

Active, not recruiting

Nov 2016161 participants

A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872

Phase 1

Completed

interventional

Jul 201668 participants

Page 1 of 3

Approvals

No approval data available

News

No news articles found

Back to Organizations